Literature DB >> 17936685

Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome.

Süreyya Savaşan1, Indira Warrier, Steven Buck, Joseph Kaplan, Yaddanapudi Ravindranath.   

Abstract

Evans' syndrome (ES) is characterized by autoimmune hemolytic anemia and thrombocytopenia and has been associated with immune deficiency and lymphoproliferation in some cases. Abnormalities of Fas-mediated apoptosis have been reported in various immune dysregulation disorders associated with autoimmunity and lymphoproliferation. We measured lymphocyte Fas expression and Fas-mediated T lymphocyte apoptosis in 7 children with ES, 7 with acute idiopathic thrombocytopenic purpura (ITP) and 9 with non-immune-mediated disorders. Patients with ES had higher Fas expression on peripheral blood T and B lymphocytes (P<0.001 and P=0.046, respectively) and increased Fas-mediated elimination of activated T lymphocytes compared with the control groups. While two ES patients had panhypogammaglobulinemia at testing, three more developed it later, reaching a frequency of 83%. Some children with ES have increased lymphocyte Fas expression and Fas-mediated T lymphocyte apoptosis and these may be early signs of common variable immunodeficiency disorder in ES.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936685     DOI: 10.1016/j.clim.2007.08.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

Review 1.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

2.  Neurological Involvement in Childhood Evans Syndrome.

Authors:  Thomas Pincez; Bénédicte Neven; Hubert Ducou Le Pointe; Pascale Varlet; Helder Fernandes; Albane Gareton; Guy Leverger; Thierry Leblanc; Hervé Chambost; Gérard Michel; Marlène Pasquet; Frédéric Millot; Olivier Hermine; Alexis Mathian; Marie Hully; Hélène Zephir; Mohamed Hamidou; Jean-Marc Durand; Yves Perel; Judith Landman-Parker; Fréderic Rieux-Laucat; Nathalie Aladjidi
Journal:  J Clin Immunol       Date:  2019-01-22       Impact factor: 8.317

Review 3.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

Review 4.  Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children.

Authors:  Lindsey A George; David T Teachey
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

Review 5.  Diagnosis and management of autoimmune cytopenias in childhood.

Authors:  David T Teachey; Michele P Lambert
Journal:  Pediatr Clin North Am       Date:  2013-10-05       Impact factor: 3.278

6.  Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.

Authors:  Emma Westermann-Clark; Cristina Adelia Meehan; Anna K Meyer; Joseph F Dasso; Devendra Amre; Maryssa Ellison; Bhumika Patel; Marisol Betensky; Charles Isaac Hauk; Jennifer Mayer; Jonathan Metts; Jennifer W Leiding; Panida Sriaroon; Ambuj Kumar; Irmel Ayala; Jolan E Walter
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

7.  Association of autoimmune hepatitis type 1 in a child with Evans syndrome.

Authors:  Chaowapong Jarasvaraparn; Hamayun Imran; Abdul Siddiqui; Felicia Wilson; David A Gremse
Journal:  World J Hepatol       Date:  2017-08-18

8.  Autoimmune cytopenias in common variable immunodeficiency.

Authors:  Jenna C Podjasek; Roshini S Abraham
Journal:  Front Immunol       Date:  2012-07-24       Impact factor: 7.561

Review 9.  Evans syndrome: clinical perspectives, biological insights and treatment modalities.

Authors:  José Carlos Jaime-Pérez; Patrizia Elva Aguilar-Calderón; Lorena Salazar-Cavazos; David Gómez-Almaguer
Journal:  J Blood Med       Date:  2018-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.